Biomedical stocks beat the bleak

buy Gabapentin overnight delivery Large Cap biomedical stocks held firm on another volatile but down day in the market driven by a host of macro and fundamental factors: earnings, Davos, Greece,China, politics, Bernanke confirmation, strong dollar, jobs, etc. In this convoluted market the technology leader Apple ( PE 26.6,EPS $7.49) with their iPad launch does not threaten Amazon’s (PE […]

Continue Reading 0

Gilead Sciences revenues and profits up sharply on antiviral drugs

enter site Gilead (GILD) shares were up 6% to $47.75 after the close as the Company announced record sales and earnings. Full Year total Revenues were $7.01B up 31% over 2008. Full Year Non-GAAP EPS were $3.06 up 40% over 2008. Fourth Quarter Non-GAAP EPS were $0.93 up 49% over 2008. Average analysts revenue estimates for 2010 […]

Continue Reading 0

Amgen Earnings just OK; January effect for BIO topped out

see AMGN-Top line revenue slowing One of the largest biotech companies reported earnings within estimates with full year 2009 EPS of $4.91 up 8% on Revenue of $14.6B down 2%.2010 Total Revenue is expected to be in the $15.1B to $15.5B range with adjusted EPS at $5.05 to $5.25.U.S. Product Sales were $11.13B a decrease of […]

Continue Reading 0

Waxman Power Play to squeeze Biotech for “biogenerics”

It is hard to believe but the Obama administration wants to open up a new political front at the last minute to squeeze the biotechnology industry after everyone thought the 12 year protection from generic biologicals was a “done deal”. Last-ditch lobbying battle over biotech drugs By ALAN FRAM The Associated Press Thursday, January […]

Continue Reading 0

JPMorgan Healthcare Conference 2010: Themes and News

Here are some of the broader themes and market trends gleaned from Company presentations: 1.) There is a shift from small molecule drug development to biologicals and vaccines. e.g. Pfizer (PFE) 2.) “Bolt-on” acquisitions of smaller companies are being done to bolster product portfolios and emerging market positions. e.g. GSK 3.) There is increasing synergy […]

Continue Reading 0

JPMorgan Healthcare Conference-2010 Day One-Monday January 11

Over 5000 people piled into the Westin St. Francis Hotel in San Francisco for the 28th Annual Conference. Investors, Company presenters and entrepreneurs were emboldened by good biotech sector returns in 2009 of 18-28% with many stocks reaching new highs. Seasonality has been a factor with the so-called “January effect” where small cap stocks tend […]

Continue Reading 1

JPMorgan Healthcare Conference Jan.11-14 San Francisco

We will be attending the 28th Annual JPMorgan Healthcare Conference in San Francisco and reporting on various companies and news on the Genetic Engineering News WEB site ( Although we will be attending presentations of companies in all sectors we will try to focus on the following: Diagnostics e.g, GenProbe, Idexx, Inverness Genomics e.g. Celera, […]

Continue Reading 0

Volcano(VOLC) erupts 9% on Upgrade

Robert W. Baird and Co. analyst Lawrence Neibor upgraded four medtech stocks and helped get the “January effect” in full swing. Cyberonics (CYBX), Edwards Lifescience (EW), Thoratec (THOR) and Volcano (VOLC) were all upgraded to Outperform from Neutral. Volcano was up 9% to 19 in late afternoon trading on 640k shares and is up about […]

Continue Reading 0

Review of Biotech 2009 Fund and ETF Performance YTD

The Rayno LifeScience Biotech portfolio is up 11-15% YTD (15%+ with rebalancing as recommended). Among the big winners YTD are Regeneron (REGN) up 40%, Targacept (TRGT) up 880% and Inverness (IMA) up 72%. The portfolio included both biotech and diagnostic companies. We reviewed five other ETFs and funds in the biotech space. The % performance […]

Continue Reading 0

CompuGen(CGEN) deal sparks small cap biodiscovery stocks

CompuGen, an early stage drug and diagnostic discovery Company announced today a “Discovery on Demand” therapeutic peptide collaboration with Pfizer that focuses on three peptide drugs based upon CompuGen in silico discovery platforms. The predicted molecules will be synthesized and delivered to Pfizer for further development. Pfizer will have the right to exercise options for […]

Continue Reading 0